Valuation : Curis, Inc.

Market Cap 2.88M 2.48M 2.33M 2.13M 3.98M 273M 4.01M 27.55M 10.73M 139M 10.83M 10.59M 449M P/E 2026 *
-0.06x
P/E 2027 * -0.19x
Enterprise Value 2.88M 2.48M 2.33M 2.13M 3.98M 273M 4.01M 27.55M 10.73M 139M 10.83M 10.59M 449M EV / Sales 2026 *
-
EV / Sales 2027 * 0.31x
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Curis, Inc.

1 day+1.09%
1 week-7.33%
Current month-6.71%
1 month-73.01%
3 months-86.10%
6 months-92.98%
Current year-92.96%
1 week 1.36
Extreme 1.36
1.58
1 month 1.36
Extreme 1.36
5.28
Current year 1.36
Extreme 1.36
24.2
1 year 1.36
Extreme 1.36
39
3 years 1.36
Extreme 1.36
349.8
5 years 1.36
Extreme 1.36
3,492
10 years 1.36
Extreme 1.36
7,440
Manager TitleAgeSince
Chief Executive Officer 59 24/09/2018
Director of Finance/CFO 54 05/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 01/11/2003
Chairman 84 16/05/2017
Director/Board Member 71 03/06/2010
Date Insider Type Main position Quantity % Market Cap. Importance
07/07/26 Free

Chief Executive Officer

110,090 0.2824%
07/07/26 Free

Director

6,800 0.0174%
07/07/26 Free

Chairman

6,800 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
+1.09%-7.33%-95.96%-99.38% 2.88M
-0.24%-1.09%+2.00%+17.50% 50.14B
+1.09%-4.38%+431.73%+527.69% 44.85B
+1.73%+2.12%+45.13%+21.30% 43.43B
+0.37%-2.64%+7.85%+77.04% 41.14B
+0.43%-3.26%+14.75%+49.08% 32.92B
+1.31%+8.56% - - 17.56B
-0.91%-3.94%+22.08%+121.60% 16.55B
+0.93%+0.63%+16.86%+29.29% 14.65B
-0.69%-2.28%+78.43%+41.78% 13.93B
Average +0.47%-1.73%+58.10%+87.32% 27.52B
Weighted average by Cap. +0.50%-1.13%+92.91%+129.18%

Financials

2026 *2027 *
Net sales - 9.25M 7.96M 7.47M 6.83M 12.75M 874M 12.85M 88.35M 34.41M 447M 34.74M 33.98M 1.44B
Net income -52.02M -44.76M -42M -38.43M -71.72M -4.92B -72.29M -497M -193M -2.51B -195M -191M -8.09B -45.23M -38.92M -36.52M -33.41M -62.36M -4.28B -62.86M -432M -168M -2.19B -170M -166M -7.04B
Net Debt - -
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
22
Date Price Change Volume
03/09/26 $1.390 +0.72% 54,402
02/09/26 $1.380 -2.82% 85,272
01/09/26 $1.420 -4.70% 65,423
31/08/26 $1.490 0.00% 35,842
28/08/26 $1.490 -0.67% 119,833
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.380USD
Average target price
42.67USD
Spread / Average Target
+2,991.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRIS Stock